These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1909485)

  • 1. Lisuride plus selegiline in the treatment of early Parkinson's disease.
    Nappi G; Martignoni E; Horowski R; Pacchetti C; Rainer E; Bruggi P; Runge I
    Acta Neurol Scand; 1991 Jun; 83(6):407-10. PubMed ID: 1909485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
    Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P
    Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():165-9. PubMed ID: 2515722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1991; 136():95-8. PubMed ID: 1801545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
    Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
    Rabey JM; Streifler M; Treves T; Korczyn AD
    Adv Neurol; 1990; 53():451-5. PubMed ID: 2122652
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selegiline dosing on motor fluctuations in Parkinson's disease.
    Hubble JP; Koller WC; Waters C
    Clin Neuropharmacol; 1993 Feb; 16(1):83-7. PubMed ID: 8422661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.